Dr. Doberstein brings extensive biotech leadership experience as the company advances its AI-powered pipeline into Phase 2 for immune-mediated inflammatory disorders
Two oral presentations will highlight research related to Invea’s lead program INVA8001 and the therapeutic impact on mast cell-driven chronic inflammatory diseases
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic …
InveniAI to Participate in the Truist Securities… Read More »
Kyowa Hakko Kirin signs AI drug R&D deal with InveniAI
Decoding the Mechanisms that Drive Chronic Inflammation to Develop Medicines for Immune-Mediated Inflammatory Disorders
2614 Boston Post Road, Suite #33AR
Guilford, CT 06437, USA
Decoding the Mechanisms that Drive Chronic Inflammation to Develop Medicines for Immune-Mediated Inflammatory Disorders
2614 Boston Post Road Suite #33AR
Guilford, CT 06437, USA
© 2024 Invea Therapeutics, Inc. All rights reserved | Privacy Policy | Terms of Use